1Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA, 2004, 291 : 1972-1977. 被引量：1
2Owens MA, Horten BC, Da silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer Inst, 2002, 5:63-69. 被引量：1
3Birner P, Oberhuber G, Stani J, et al. Evaluation of the United States Food and Drug Administration-approved Scoring and test system of HER2 protein expression in breast cancer. Clin Cancer Res, 2001, 7:1669-1675. 被引量：1
4Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment group N9831 Intergroup adjuvant trial. J Clin Oncol, 2006, 24:3032-3038. 被引量：1
5Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst, 2002, 94:855-857. 被引量：1
6Perez EA, Roche PC, Jenkins RB, et al. HER2 testing in patients with breast cancer: Poor correlation between weak positive by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc, 2002, 77:148-154. 被引量：1
8Wolff AC, Hammond ME, Schwarts JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol, 2007, 25 : 118-145. 被引量：1
9Nunes CB, Rocha RM, Reis-Filho JS, et al. Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridization in breast carcinomas. J Clin Pathol, 2008,61:954-938. 被引量：1
10Gown AM, Goldstein LC, Barry TS, et al. High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system. Mod Patholo, 2008,21:1271-1277. 被引量：1
